Remedi레메디

Remedi is a recently listed Korean medical device company whose shares have swung sharply, with no reported profit figures in the data provided.

Remedi listed on KOSDAQ on 2026-07-13 and closed at ₩14,110 on 2026-10-22, giving a market value of about ₩107.6B. The share price is well below its 52-week high of ₩34,650 but far above its low of ₩6,980, and it is down 9.1% over one month and up 23.8% over three months. Trailing revenue, operating income and net income are not available in the data, so profitability cannot be judged from this pack.

What stands out

• Price-to-book is about 6.8x, well above the peers listed (roughly 3.2x to 21.1x, with several near 5x or higher), while earnings-based multiples are not available for Remedi.
• Borrowings of about ₩4.33B against cash of about ₩1.70B, with liabilities at 103% of equity, show a meaningful debt load relative to cash.
• Recent filings are mostly routine governance items: a shareholders' meeting notice, record-date setting, the half-year report for June 2026, and several insider and 5%+ holding reports.
• News headlines from October 2026 highlight expansion in India, reportedly reaching 2,301 medical institutions, and expected public procurement growth in Southeast Asia; the headlines do not include financial figures.
• Foreign ownership rose slightly from 0.9% to 1.1% over about 60 days, while institutions were net sellers over the last 20 days.

What to watch

• The next periodic results and whether the India and Southeast Asia expansion shows up in reported revenue and profit, which the data does not yet show.
• Outcome of the upcoming shareholders' meeting and any further filings on share issuance or major holdings.
• Share price volatility and the company's debt levels, given the large swings in the stock and no reported earnings in the data.